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Abstract
Background: Chronic HCV Patients taking PEG-IFN-α/R from different ethnic groups have different probabilities of
reaching a sustained viral response (SVR). There are many influence factors, such as HCV genotype, IL-28B single-
nucleotide polymorphisms (SNP), Fibrosis 4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index
(APRI) score. But the baseline factors in relation to treatment outcome was still not much clear.
Methods: We evaluated data from 231 chronic HCV patients with or without liver fibrosis and their antiviral efficacy
after treatment with pegylated interferon plus ribavirin (PEG-IFN-α/R) for 24–48 weeks. IL-28B SNP and HCV genotypes
were analyzed with genome sequencing using pyrosequencing.
Results: Sustained viral response (SVR) rates of patients with HCV 1b and 2a genotypes were 52.25% (58/111)
and 75.28% (67/89) (P < 0.01). SVR rates of patients with IL-28B rs8099917 TT, rs12979860 CC and rs12980275 AA were
92.41% (25/27), 92.86% (26/28) and 88.89% (24/27) separately. We found that SVR rates in HCV 1b and 2a patients were
only 31.0 and 39.4% if their FIB-4 > 3.25. In addition, when their APRI > 2, only 30.3% of HCV 1b patients and 50.2% of
HCV 2a patients could obtain SVR.
Conclusions: There were high proportion of HCV genotype 1b and 2a in Northwest China. In both HCV 1b and 2a
genotypes, patients with protective-genotype of IL-28B were more likely to obtain SVR. However, those with significant
fibrosis or cirrhosis were less likely, no matter their genotype. Combined factors of HCV genotype, IL-28B genotype,
FIB-4 and ARPI may indicate high prediction and clinical value regarding treatment with PEG-IFN-α/R and prognostic
evaluation of chronic hepatitis C patients.
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Background
Hepatitis C is an infectious disease that is widely spread
geographically. It has been reported that about 180
million people are infected with the hepatitis C virus
(HCV) worldwide, accounting for about 3% of the
current population [1]. The incidence of infection can be
easily neglected and thus may develop into cirrhosis and
even HCV-related hepatocarcinoma and liver failure,
which pose serious threats to human health. More than
0.35 million people have died from HCV-related liver
disease [2]. The application of pegylated interferon
(PEG-IFN)-alpha combined with ribavirin (PEG-IFN-α/R)
had been considered to be the most popular and effective
therapy in blocking virus replication before 2015 [3].
While the novel sofosbuvir-ledipasvir opened a new time
for treatment of eligible HCV-infected patients with
90–100% efficiency [4, 5]. Unfortunately sofosbuvir is
much more expensive, with an estimated cost of an
additional $65 billion during the next 5 years [6]. It
should be carefully thought about the necessity and
how much people have to take DAA drugs. And it is
not the time to ignore the application of PEG-IFN-α/R,
especially in China.
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Patients taking PEG-IFN-α/R from different ethnic
groups have different probabilities of reaching a sustained
viral response (SVR). In the United States, the rate of
obtaining SVR in the black population is almost 50% less
than of white patients, and the probability of obtaining
SVR in white patients with HCV genotype 1 treated by
PEG-IFN-α/R is approximately 42–53% [7]. In China, the
SVR rate was a light higher, could reach 65.3% [8]. We
recently found that northwest patients of China seem to
have higher SVR that was 72.6%. Because there were
seldom immigrant in the northwest population, the high
SVR is reasonable caused by geographic specificity, such
as genotype of HCV and polymorphisms of IL-28B.
Determination of HCV genotype is important to pre-
dict response to antiviral therapy and time of treatment
[9]. Early clinical trials have reported that SVR rates for
patients with genotype 1 (42–46%) are lower than rates
for patients with non-type 1 genotype (76–82%) [10].
On the other hand, genome-wide association studies
have suggested that host IL-28B single-nucleotide poly-
morphisms (SNP) rs12979860 CC and rs8099917 TT are
significantly correlated with SVR in patients receiving
PEG-IFN-α/R treatment [11]. The probability of obtain-
ing SVR is further reduced in vivo if IL-28B is mutated
in patients with HCV genotype 1 infection [12, 13].
Liver fibrosis had been suggested being closely associated
with the risk of HCC development in chronic hepatitis C
patients [14]. The eradication of HCV with antiviral therapy
will prevent the progression of chronic hepatitis and
associated complications [15]. But it was never paid
more attention in China [8].
To determine the favorable patients for treatment with
PEG-IFN-α/R, HCV genotype, IL-28B SNP, Fibrosis 4
(FIB-4) index and aminotransferase-to-platelet ratio
index (APRI) score we retrospectively analyzed with
SVR in this study.
Methods
Patients
All patients with CHC were enrolled for this research
with signed informed consents following the protocols
approved by the Institutional Review Board of the
Fourth Military Medical University (Table 1). Inclu-
sion criteria: patients were firstly diagnosed as HCV
infection since August 2013, naive-treatment from
October 2013 and HCV RNA > 1000 IU/mL. Exclu-
sion criteria: Patients with recurrence of hepatitis C,
hepatitis infected with HAV, HBV, HDV, HEV, EBV
or CMV; HIV infection, Diabetes, autoimmune liver
disease and HCC etc. were excluded.
We collected data on 230 patients with chronic HCV
infection who were seen at Xijing Hospital from October
2013 to February 2016. The average age was 46.71 years
(range, 20–80 y), with 112 male and 118 female patients.
Patients had been treated with standard of care for
24–48 weeks. PEG IFN-α/RBV: The recommended
dose of PEG IFN-α-2a (Pegasys Roche Shanghai) for
chronic hepatitis C was 180 ug per time, once a week,
subcutaneous injection of the abdomen or thigh. The dose
of RBV was determined by the genotype of virus: the dose
for genotype 2 or 3 was 800 mg a day for 24 weeks, and
the dose of genotype 1 was 1000–1200 mg daily according
to body weight, for 48 weeks. We mainly investigated
outcomes after 24 weeks.
There are many serological markers for HCV or evi-
dence of liver disease including HCV RNA was used to
understand the activity of virus replication, ALT, AST,
Total bilirubin, direct bilirubin, indirect bilirubin, albu-
min, globulin, choline esterase, alkaline phosphatase,
phosphatase and abdominal ultrasound were used for
evaluation of liver damage, CT or MRI was used to be
clear of the extent of liver damage. Liver biopsy is the
gold standard for evaluation of liver inflammation and
Table 1 Clinical characteristic of patients with different HCV genotypes
HCV
Genotype






1a 12 39.67 (24–60) 7 (58.33) 5 (41.67) 2.33 (0.01–29.90) 58.17 (19–249) 37.08 (10–157)
1b 111 46.81 (20–79) 52 (47.27) 58 (52.73) 1.62 (0.02–46.1) 50.15 (13–392) 44.96 (16–453)
2a 89 50.45 (22–80) 40 (44.94) 49 (55.06) 2.60 (0.00–18.10) 49.38 (12–554) 35.25 (15–205)
2b 1 54.00 (54–54) 0 (100.00) 1 (0.00) 1.08 286.00 351.00
3a 11 37.91 (25–53) 8 (72.73) 3 (27.27) 5.52 (0.21–29.5) 91.27 (37–340) 50.36 (32–160)
3b 5 38.00 (23–45) 3 (60.00) 2 (40.00) 1.71 (0.10–6.88) 52.40 (58–204) 37.00 (44–141)
4a 0
5a 1 43.00 (43–43) 2 (100.00) 0 (0.00) 0.00 0.00 0.00
6a 1 25.00 (25–25) 1 (100.00) 0 (0.00) 0.00 0.00 0.00
Z = 3.6464 chi-squared =0.643 Z = 1.8797 Z = 0.6820 Z = 0.6820
P value .067 .836 .113 .605 .605
The low number of patients with 2b, 4a, 5a and 6a did not meet the statistical requirements; therefore, these were excluded for follow-up statistics
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fibrosis staging in patients. In addition, there were also
patient compliance issues. After careful consideration we
chose these common and easy to get markers as ALT
and AST for liver damage, FIB-4 and APRI to evaluate
liver fibrosis. Use of viral content to evaluate curative
effect was according to the 2014 European Association
for the Study of the Liver Recommendations on Treat-
ment of Hepatitis C and the Guideline of Prevention
and Treatment of Hepatitis C [16, 17]. We evaluated
SVR using quantitative real-time fluorescence polymer-
ase chain reaction (ViiA7 OX, Life Technology) of HCV
RNA (less than 15 IU/mL) for at least 24 weeks of
follow-up at the end of treatment. Samples were col-
lected and separated from the peripheral blood and
serum and then stored at −20 °C until analyses.
DNA/RNA extraction
For DNA extraction for IL-28B gene detection, we used a
blood genomic DNA extraction kit (Tiangen, Beijing,
China). For HCV RNA extraction, we used the MinElute
column QIAamp method and the virus genome DNA/RNA
extraction kit (Tiangen). All extracted DNA/RNA were then
immediately used for gene detection or stored at −80 °C.
Quantitative real-time fluorescence PCR
Primer sequences were designed by using DNAMan
6.0.3.99 (LynnonBiosoft, San Ramon, CA, US) for
IL-28B gene amplification, including IL-28B rs8099917,
IL-28B rs12979860 and IL-28B rs12980275 genes
(Table 2). Among them, 5’of 3reversed primers were la-
beled with biotin. Amplification included heating at 95 °C
for 5 min, 95°Cfor 20 s, and 60 °C for 20 s, with steps re-
peated for 40 cycles. Amplification was run on a 7500 fast
real-time PCR system (Applied Biosystems, Foster City,
CA, USA). HCV genotype was measured by using an
HCV genotyping PCR kit (Qiagen, Beijing, China), follow-
ing the manufacturer’s protocol.
Gene sequencing
IL-28B gene polymorphism was detected with the use of
a pyrosequencing method on Q24MDX (Qiagen, Hilden,
Germany). Sequencing primers were designed by the
Q24 PyroMark. HCV polymorphism sequencing primers
were also provided by Qiagen.
Liver fibrosis staging
The degree of liver fibrosis was evaluated with APRI score,
which can be used for the assessment of liver cirrhosis [18].
APRI scores > 2 in adults indicate that the patient has
already had liver cirrhosis. The APRI score is calculated as
follows: (aspartate aminotransferase [AST]/ULN) × 100/
platelets (109/L), where ULN is the upper limit of normal
value. Fibrosis-4 index was based on values of ALT, AST,
platelet count and patient age. This index can be used to
diagnose liver fibrosis (similar to least significant fibrosis
using METAVIR F scoring system ≥2) [19]. A significant
liver fibrosis has occurred if a patient shows aFIB-4 index
of >3.25. FIB-4 is calculated as follows: age ×ALT (IU/L)/
(platelet count [109/L] × AST [IU/L]) 1/2.
Statistical analyses
We used Pearson chi-squared and Kruskal-Wallis tests
to analyze the qualitative data with SPSS 19.0 (IBM,
USA.). A logistic regression model was used to analyze
the correlation between SNPs (IL-28B rs8099917, IL-28B
rs12979860 and IL-28B rs12979860) and SVR of
patients. Odds ratio (OR) was used to describe the cor-
relating degree of disease and exposed factors. OR tests
were two-sided tests, in which P < 0.05 was considered
to be statistically significant.
Results
HCV genotype and distribution
HCV genotypes of 230 patients with chronic HCV infec-
tion were sequenced, with results shown in Table 2. One
patient had mixed infection of 1b and 5a. For statistical
analyses, this patient was analyzed in both the 1b and 5a
genotype groups. Statistical results of 1a, 1b, 2a, 2b, 3a,
3b, 4a, 5a and 6a genotypes are presented in Fig. 1. The
ratio of genotypes were as follows: 5.19% with 1a
(12/230),48.05% with 1b (111/230),38.53% with 2a
(89/230),0.43% with 2b (1/230),4.76% with 3a (11/
230),2.16% with 3b (5/230),0% with 4a (0/230),0.43%
with 5a (1/230), and 0.43% with 6a (1/230). There
were no significant differences in age, sex, viral load
and alanine aminotransferase (ALT) and aspartate
transaminase (AST) levels (P > 0.05).
IL-28B genotype in patients with chronic HCV infection
Fifty-one patients with HCV were included in the
IL-28B gene polymorphism loci analyses (Table 3). Of
the IL-28B genotypes, 76.47% of patients were














rs12980275: 5′- GAAGTCAAATTCCTAGAAA −3′
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rs8099917 TT, 76.47% were rs12979860 CC, and 72.55%
were rs12980275 AA. We also found that 5.88% of the
IL-28B genotypes were rs8099917 GG, rs12979860 TT
or rs12980275 GG. Details of clinical features are pre-
sented in Table 3. Statistical results showed no statistical
differences in age, sex, viral load and ALT and AST
levels (P > 0.05).
Correlation between HCV genotypes and antiviral efficacy
HCV genotypes 1b and 2a accounted for 86% of all
samples; therefore, we mainly evaluated the correlation
between these 2 genotypes and antiviral efficacy. SVR
rates in patients with HCV genotype 1b and HCV geno-
type 2a were 52.25% (58/111) and 75.28% (67/89), with
differences being statistically significant (chi-squared =21.56;
P < 0.01). In patients with HCV genotype 1b, 70.67% (53/75)
did not reach SVR (Fig. 2a).
Role of IL-28B gene polymorphism in antiviral efficacy
We used SNP Stats Software (http://bioinfo.iconcolo-
gia.net/snpstats/start.htm [13]) for correlation analyses.
After adjusting for confounding factors (including age,
sex, viral load, ALT and AST), we found that there was
a correlation between patients with SVR and IL-28B
genotype (P < 0.05), with OR (95% confidence interval)
of11.02 (3.98–23.16) for rs8099917, 10.20 (5.23–22.14)
for rs12979860 and 10.08 (2.98–18.59) for rs12980275.
Figure 2b show that patients with chronic HCV infec-
tion the SVR rate of IL-28B rs8099917 TT was (25/
27,92.41%), IL-28B rs12979860 CC was (26/28, 92.86%)
and IL-28B rs12980275 AA was (24/27, 88.89%). In
contrast, only 7.41, 7.14 and 11.11% reached SVR
with IL-28B SNP rs8099917 TG +GG, rs12979860
CT + TT, and rs12980275 AG +GG, respectively.
Patients with protective genotypes were more likely to
obtain SVR.
Fig. 1 Distribution of HCV genotype. 86% of the patients with HCV infection were genotype 1 and 2, with 1b accounting for 48.05% and 2a
accounting for 38.53%, followed by 1a (5.19%), 3a (4.76%), 3b (2.16%), 2b (0.43%), and 6a (0.43%)
Table 3 IL-28B gene polymorphism in patients with chronic HCV infection and clinical characteristics of patients with different
IL-28B SNPs








76.47 48 (25–64) 54 (52.9) 52 (47.1) 7.98 (0.24–72.46) 34 (18–179) 38 (17–203)
TG + GG
(n = 12)
23.43 47 (22–58) 21 (55.3) 16 (44.7) 9.25 (0.89–59.71) 36 (28–150) 40 (24–138)
IL-28B rs12979860 CC
(n = 39)
76.47 49 (22–64) 57 (52.3) 52 (47.7) 10.23 (1.02–68.52) 35 (21–112) 32 (19–143)
CT + TT
(n = 12)
23.43 49 (20–58) 18 (52.9) 16 (47.1) 8.72 (0.48–65.32) 37 (19–135) 34 (17–178)
IL-28B rs12980275 AA
(n = 37)
72.55 47 (28–64) 51 (51.5) 48 (48.5) 11.25 (1.37–66.68) 38 (22–144) 31 (20–123)
AG + GG
(n = 14)
27.45 46 (25–59) 24 (54.5) 20 (45.5) 9.67 (0.69–71.26) 32 (19–179) 29 (17–112)
Z = 0.125 chi-squared = 0.413 Z = 0.579 Z = 0.378 Z = 2.143
P value .912 .648 .825 .617 .346
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Role of IL-28B SNP and HCV genotype in antiviral efficacy
We combined the results of IL-28B SNP and HCV geno-
type and analyzed the correlation between these factors.
We found that 12/51 patients with HCV genotype 1b
infection obtained SVR, in which 8/12 cases were
rs12979860 CC (shown in Fig. 2c). We also found that
the 7 of10 patients infected with HCV genotype 2a who
obtained SVR were rs12979860 CC. In addition, 2 in 17
patients with HCV genotype 1b infection and SNP
rs12979860 CC did not obtain SVR, and only 1/3 pa-
tients with HCV genotype 2a infection and SNP
rs12979860 CC did not obtain SVR. Patients HCV geno-
type 2a infection with IL-28B SNP rs12979860 CC were
more likely to reach SVR.
Association of liver fibrosis staging and cirrhosis in
patients with chronic HCV infection and antiviral efficacy
Because there were only 190 out of 231 patients did PLT
detection, and APRI and FIB-4 were calculated accord-
ing to results of patients’ PLT. So APRI score and FIB-4
index were calculated in 190 of 231 patients with
chronic HCV infection. Sixty patients had FIB-4 index >
3.25, including 32 patients with genotype 1b infection
and 21 patients with genotype2a infection. In this patient
group, 31.0% of patients with HCV genotype 1b (19/
32 × 58/111) and 39.4% of patients with genotype 2a (11/
21 × 67/89) reached SVR (not statistically significant; P >
0.05). Thirty-nine patients had APRI score > 2, including
11 patients with genotype 1b and 8 patients with geno-
type 2a infection. In this patient group, 30.3% with HCV
genotype 1b (11/19 × 58/111) and 50.2% with genotype
2a (8/12 × 67/89) reached SVR (P < 0.05). Although we
could not prove that genotype affected the ability to
reach SVR in patients with cirrhosis (APRI > 2), we did
observe that APRI score > 2 significantly affected SVR.
Details are shown in Tables 4 and 5.
Fig. 2 a Correlation between HCV genotype distribution and SVR. Sustained viral response (SVR) rates by HCV genotypes 1b and 2a were 52.25%
(58/111) and 75.28% (67/89), statistically significant at P < 0.01. Rates of patients with HCV genotype 1b and 2a who did not reach SVR were 70.67
and 29.33%. Relationship between IL-28B genotype and SVR was showed in (b). SVR rates in patients of chronic HCV infection with different IL-28
single-nucleotide polymorphisms (SNP) (rs8099917 TT, rs12979860 CC and rs12980275 AA) were 92.41% (25/27), 92.86% (26/28), and 88.89% (24/27),
respectively. In contrast, only 7.41, 7.14 and 11.11% of patients with IL-28B rs8099917 TG + GG, rs12979860 CT + TT, and rs12980275 AG +GG obtained
SVR. c showed correlation among IL-28B SNP, HCV genotype and SVR
Table 4 Characteristics of patients
Variables No. of Patients (%of Total)
Total number of patients 231
Age ± standard deviation, y 46.71 ± 14.34
Male 113
Female 118
APRI data 190 (82.3)
FIB-4 data 190 (82.3)
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Discussion
China has shown a new trend in HCV infection, with
epidemic levels of genotypes1, 2, 3 and 6 and no geno-
types 4 or 5 found. The most common genotype in
China is1b and 2a, with incidence rates of 73.1 and
18.5%, followed by genotypes 3a, 6a, 3b and 1a. Geno-
types 3 and 6 are geographically distributed more widely
[20]. In our group, which included 230 patients with
chronic HCV infection, sequencing results showed that
the incidence of HCV in the Shaanxi region was > 86%
with genotypes 1 and 2, with much lower numbers with
genotypes 3 and 6, and none with genotype 4. More pa-
tients had genotype 1b (48.05%) and 2a (38.53%),
followed by 1a, 3a, 3b, 2b and 6a. The high percent of
genotype 2a might be one important reason for high
SVR. And we truly found that patients with genotype 2a
had greater SVR rates (75.28%) than patients with geno-
type 1b (52.25%). The results have a slight discrepancy
versus the previous reports, which SVR rates for patients
with genotype 1 were 42–46% and non-type 1 genotype
were 76–82% [10, 21–23].
Furthermore, our SNP analysis results of 51 patients
with chronic HCV infection (IL-28B rs8099917, IL-
28B rs12979860 and IL-28B rs12980275 SNP) and
sequencing results of 230 patients with chronic HCV
infection showed that more patients had IL-28B
rs8099917 TT versus rs8099917 GG, more had IL-28B
rs12979860 CC versus TT, and more had IL-28B
rs12980275 AA versus GG in Northwest China, simi-
lar to some previous reports [24, 25]. Presence of
rs8099917 is one of the independent predictors in HCV
1b patients treated with PEG-IFN-α/R or interferon-α 2
only. Presence of rs12980275 has great relevance with
SNP of rs12979860 [26], which plays an important role in
the prediction of SVR in HCV patients treated with
PEG-IFN-α/R, particularly in patients with HCV genotype
1 or 4 [10, 27]. So rs8099917TT, rs12979860CC, and
rs12980275AA were considered to be protective geno-
types [28]. In this study, SVR rates of patients with IL-28B
rs8099917 TT, rs12979860 CC and rs12980275 AA
were 92.41% (25/27), 92.86% (26/28) and 88.89% (24/
27) separately. SVR rates in patients with protective
genotypes accounted for more than sixty percent of
total, whereas the SVR rates of non-protective
genotypes were very low. This suggested that the pro-
tective IL-28B genotypes were more likely to result in
patients with chronic HCV infection obtaining SVR,
which is consistent with previous reports [26–29]. In
addition, we corrected for age, sex, AST and ALT
levels, HCV genotype and other factors with the use
of SNPStats software [30] and found that patients
with chronic HCV infection who obtained SVR
24 weeks after standard of care antiviral treatment
were closely related to HCV genotype and IL-28B
SNP (P < 0.05). That means more than sixty percent
of patients are suitable for PEG-IFN-α/R treatment.
Well, the major limitation in this part of study is that
the sample amount was relatively too small to deter-
mine the role of IL-28B gene polymorphism in
antiviral efficacy. However, our findings were in
accordance with previous data [26–29].
Interestingly, we found that differences in cirrhosis
progression between 1b and 2a were statistically signifi-
cant, confirming that HCV genotype can influence the
progression of liver cirrhosis. FIB-4 index > 3.25 or APRI
score > 2 indicated that patients had significant liver
fibrosis or even cirrhosis [31]. In this study, the SVR
rates of patients with FIB-4 index > 3.25 and genoty-
pes1b and 2a were 31.0 and 39.4%, respectively, which
were much lower than that shown in patients with geno-
type 1b (62.06%) and genotype 2a (74.54%) with FIB-4
index ≤ 3.25. This indicated that patients with obvious
liver fibrosis were less likely to reach SVR, which was
associated with HCV genotype (1b or 2a). In addition,
SVR rates of patients with APRI score > 2 were 30.3% for
genotype 1b and 50.2% for genotype 2a. The large differ-
ence indicated that patients with cirrhosis had greater
difficulty reaching SVR, for both HCV genotype 1b and
2a, and the progression of cirrhosis (APRI > 2) could be
influenced by genotype. The clearance of HCV in
patients with advanced-stage liver fibrosis can reduce
the incidence of decompensated liver cirrhosis.
Conclusions
There were high proportion of HCV genotype 1b and
2a in Northwest China. In both HCV 1b and 2a ge-
notypes, patients with protective-genotype of IL-28B
Table 5 FIB-4 index, APRI scores and SVR of patients
Genotype No. of Patients
(% of Total)
No. of Patients with
FIB-4 > 3.25 (% of Total)
No. of Patients with
APRI > 2 (% of Total)
Total SVR (%) No. of Patients with
FIB-4 > 3.25 and SVR (%)
No. of Patients with
APRI > 2 and SVR (%)
1b 90 (81.1) 32 (16.8) 19 (10.0) 58 (64.4) 19 (31.0) 11 (30.3)
2a 76 (85.4) 21 (11.1) 12 (6.3)* 67 (88.1) 11 (39.4) 8 (50.2)
Other 24 (77.4) 7 (3.7) 8 (4.2) 13
Total 190 (82.3) 60 (31.6) 30 (20.5) 138 (72.6)
*P < 0.05
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were more likely to obtain SVR. However, those with
significant fibrosis or cirrhosis were less likely, no
matter their genotype. Combined factors of HCV
genotype, IL-28B genotype, FIB-4 and ARPI poten-
tially have a very high prediction and clinical value
regarding treatment with PEG-IFN-α/R and prognos-
tic evaluation of chronic hepatitis C patients.
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